NervGen Pharma Corp (id:1295 NGEN)
3.11 CAD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 12/25/2024 8:49:07 AM)
Exchange closed, opens in 40 minutes
7.24 CAD (7.24%)
16.92 CAD (16.92%)
45.33 CAD (45.33%)
10.28 CAD (10.28%)
20.54 CAD (20.54%)
77.71 CAD (77.71%)
55.50 CAD (55.50%)
About NervGen Pharma Corp
Market Capitalization 185.61M
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
| Headquarters (address) |
112-970 Burrard Street Vancouver V6Z 2R4 BC Canada |
| Phone | 778 731 1711 |
| Website | https://www.nervgen.com |
| Employees | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | NGEN |
| Exchange | Toronto Stock Exchange Venture |
| Currency | CAD |
| 52 week range | 1.65 - 3.98 |
| Market Capitalization | 185.61M |
| P/E trailing | -8.18 |
| P/E forward | -6.29 |
| Price/Book | 23.74 |
| Beta | 1.35 |
| EPS | 3.00 |
| EPS Canada (ID:82, base:720) | 2.18 |